Wedbush Raises Price Target on Revolution Medicines to $59 From $46, Maintains Outperform Rating
Wedbush Raises Price Target on Revolution Medicines to $59 From $46, Maintains Outperform Rating
Wedbush將Revolution Medicines的目標股價從46美元上調至59美元，維持跑贏大盤評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊